JP2006509743A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006509743A5 JP2006509743A5 JP2004550274A JP2004550274A JP2006509743A5 JP 2006509743 A5 JP2006509743 A5 JP 2006509743A5 JP 2004550274 A JP2004550274 A JP 2004550274A JP 2004550274 A JP2004550274 A JP 2004550274A JP 2006509743 A5 JP2006509743 A5 JP 2006509743A5
- Authority
- JP
- Japan
- Prior art keywords
- carbon atoms
- pharmaceutical composition
- alkyl
- phenyl
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 48
- -1 1-oxo-1,3-dihydro-isoindol-2-yl Chemical group 0.000 claims description 35
- 125000000217 alkyl group Chemical group 0.000 claims description 28
- 229910052739 hydrogen Inorganic materials 0.000 claims description 22
- 239000001257 hydrogen Substances 0.000 claims description 22
- 150000002431 hydrogen Chemical class 0.000 claims description 16
- 125000003545 alkoxy group Chemical group 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 10
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 125000001475 halogen functional group Chemical group 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 125000004442 acylamino group Chemical group 0.000 claims description 3
- 125000003282 alkyl amino group Chemical group 0.000 claims description 3
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 3
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 3
- 125000005159 cyanoalkoxy group Chemical group 0.000 claims description 2
- 125000006277 halobenzyl group Chemical group 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 230000002401 inhibitory effect Effects 0.000 claims 14
- 208000002780 Macular Degeneration Diseases 0.000 claims 10
- 239000003112 inhibitor Substances 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 239000011780 sodium chloride Substances 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 5
- 206010064930 Age-related macular degeneration Diseases 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 230000033115 angiogenesis Effects 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 239000000790 retinal pigment Substances 0.000 claims 3
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims 2
- QLNJFJADRCOGBJ-UHFFFAOYSA-N Propanamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N Thalidomide Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 2
- 229960003433 Thalidomide Drugs 0.000 claims 2
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 claims 2
- 229940079593 drugs Drugs 0.000 claims 2
- 229940080818 propionamide Drugs 0.000 claims 2
- 102100011470 ABCA4 Human genes 0.000 claims 1
- 102100012672 ARTN Human genes 0.000 claims 1
- 101700061329 ARTN Proteins 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 102100007149 BEST1 Human genes 0.000 claims 1
- 101700047202 BEST1 Proteins 0.000 claims 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 1
- 208000008069 Geographic Atrophy Diseases 0.000 claims 1
- 102000018997 Growth Hormone Human genes 0.000 claims 1
- 108010051696 Growth Hormone Proteins 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 206010023126 Jaundice Diseases 0.000 claims 1
- 206010025425 Maculopathy Diseases 0.000 claims 1
- 108010008148 Member 4 Subfamily A ATP Binding Cassette Transporter Proteins 0.000 claims 1
- 101700009327 NTF3 Proteins 0.000 claims 1
- 206010029113 Neovascularisation Diseases 0.000 claims 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 claims 1
- 241001483078 Phyto Species 0.000 claims 1
- 210000003660 Reticulum Anatomy 0.000 claims 1
- 206010062766 Stargardt's disease Diseases 0.000 claims 1
- ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N Verteporfin Chemical compound C=1C([C@@]2([C@H](C(=O)OC)C(=CC=C22)C(=O)OC)C)=NC2=CC(C(=C2C=C)C)=NC2=CC(C(=C2CCC(O)=O)C)=NC2=CC2=NC=1C(C)=C2CCC(=O)OC ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N 0.000 claims 1
- 229960003895 Verteporfin Drugs 0.000 claims 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N Xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 230000003110 anti-inflammatory Effects 0.000 claims 1
- 102000004965 antibodies Human genes 0.000 claims 1
- 108090001123 antibodies Proteins 0.000 claims 1
- 230000003078 antioxidant Effects 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 235000006708 antioxidants Nutrition 0.000 claims 1
- 235000013405 beer Nutrition 0.000 claims 1
- 230000003115 biocidal Effects 0.000 claims 1
- 239000000262 estrogen Substances 0.000 claims 1
- 239000000122 growth hormone Substances 0.000 claims 1
- 125000005059 halophenyl group Chemical group 0.000 claims 1
- 102000006495 integrins Human genes 0.000 claims 1
- 108010044426 integrins Proteins 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 230000000366 juvenile Effects 0.000 claims 1
- 238000002647 laser therapy Methods 0.000 claims 1
- 238000007726 management method Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000003900 neurotrophic factor Substances 0.000 claims 1
- 239000003504 photosensitizing agent Substances 0.000 claims 1
- 238000001126 phototherapy Methods 0.000 claims 1
- 150000003180 prostaglandins Chemical class 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 125000002345 steroid group Chemical group 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 201000007790 vitelliform macular dystrophy Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42290002P | 2002-10-31 | 2002-10-31 | |
| PCT/US2003/034535 WO2004041181A2 (en) | 2002-10-31 | 2003-10-31 | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006509743A JP2006509743A (ja) | 2006-03-23 |
| JP2006509743A5 true JP2006509743A5 (zh) | 2006-07-20 |
Family
ID=32312567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004550274A Pending JP2006509743A (ja) | 2002-10-31 | 2003-10-31 | 黄斑変性の治療および管理のための選択的サイトカイン阻害薬の使用方法およびそれを含む組成物 |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1567148A4 (zh) |
| JP (1) | JP2006509743A (zh) |
| KR (1) | KR20050062649A (zh) |
| CN (1) | CN1731997A (zh) |
| AU (1) | AU2003285107B2 (zh) |
| BR (1) | BR0315889A (zh) |
| CA (1) | CA2504263A1 (zh) |
| MX (1) | MXPA05004486A (zh) |
| NZ (1) | NZ540185A (zh) |
| TW (1) | TW200418455A (zh) |
| WO (1) | WO2004041181A2 (zh) |
| ZA (1) | ZA200503468B (zh) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7776907B2 (en) * | 2002-10-31 | 2010-08-17 | Celgene Corporation | Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide |
| US20040091455A1 (en) * | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
| CN103402980B (zh) * | 2011-01-10 | 2016-06-29 | 细胞基因公司 | 作为pde4和/或细胞因子抑制剂的苯乙基砜异吲哚啉衍生物 |
| KR101908330B1 (ko) | 2017-02-17 | 2018-10-16 | 인제대학교 산학협력단 | 신규 항-vegf 항체 및 이를 유효성분으로 포함하는 나이관련 황반변성 예방 또는 치료용 조성물 |
| BR112021009136A2 (pt) * | 2018-11-14 | 2021-08-10 | Zhuhai Qiwei Bio-Technology Ltd. | método de triagem, método para a produção de um modelo de mamíferos, modelo animal e seu método de preparação, uso de uma quantidade eficaz de um antibiótico, de um composto e de um extrato |
| FI3886852T3 (fi) * | 2018-12-03 | 2024-04-29 | Smilebiotek Zhuhai Ltd | Oktyyligallaatti ja sen estereitä käytettäväksi Bacillus megateriumin aiheuttaman ikään liittyvän silmänpohjan rappeuman hoidossa ja ehkäisyssä |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US577589A (en) * | 1897-02-23 | Valve for explosive-engines | ||
| US5605914A (en) * | 1993-07-02 | 1997-02-25 | Celgene Corporation | Imides |
| US5698579A (en) * | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
| WO1995003807A1 (en) * | 1993-07-27 | 1995-02-09 | The University Of Sydney | Treatment of age-related macular degeneration |
| NZ502379A (en) * | 1997-07-31 | 2002-10-25 | Celgene Corp | Substituted alkanohydroxamic acids and use in pharmaceuticals for reducing TNF-alpha levels |
| JP2002514578A (ja) * | 1998-05-11 | 2002-05-21 | エントレメッド インコーポレイテッド | ２−フタルイミジノグルタル酸の類似体および血管新生の阻害剤としてのそれらの使用 |
| US6020358A (en) * | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
| JP2000159761A (ja) * | 1998-11-30 | 2000-06-13 | Yoshio Takeuchi | フルオロサリドマイド |
| US6667316B1 (en) * | 1999-11-12 | 2003-12-23 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
| RU2004133811A (ru) * | 2002-04-19 | 2005-04-20 | Смитклайн Бичам Корпорейшн (US) | Новые соединения |
| JP2005530780A (ja) * | 2002-05-17 | 2005-10-13 | セルジーン・コーポレーション | 癌および他の疾患を治療および管理するための選択的サイトカイン阻害薬を用いた方法および組成物 |
| BR0315316A (pt) * | 2002-10-15 | 2005-08-16 | Celgene Corp | Métodos de tratar, prevenir ou controlar uma sìndrome mielodisplásica, e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária, e, kit |
-
2003
- 2003-10-31 ZA ZA200503468A patent/ZA200503468B/en unknown
- 2003-10-31 WO PCT/US2003/034535 patent/WO2004041181A2/en active Application Filing
- 2003-10-31 EP EP03779423A patent/EP1567148A4/en not_active Withdrawn
- 2003-10-31 MX MXPA05004486A patent/MXPA05004486A/es active IP Right Grant
- 2003-10-31 TW TW092130486A patent/TW200418455A/zh unknown
- 2003-10-31 CA CA002504263A patent/CA2504263A1/en not_active Abandoned
- 2003-10-31 BR BR0315889-6A patent/BR0315889A/pt not_active IP Right Cessation
- 2003-10-31 JP JP2004550274A patent/JP2006509743A/ja active Pending
- 2003-10-31 AU AU2003285107A patent/AU2003285107B2/en not_active Ceased
- 2003-10-31 KR KR1020057007608A patent/KR20050062649A/ko not_active Application Discontinuation
- 2003-10-31 NZ NZ540185A patent/NZ540185A/en not_active IP Right Cessation
- 2003-10-31 CN CNA2003801080906A patent/CN1731997A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11065236B2 (en) | Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor | |
| ES2521672T3 (es) | Formulaciones farmacéuticas para el tratamiento del cáncer | |
| JPH09505809A (ja) | ヒドロキシカルバゾール化合物類による平滑筋移動および増殖の阻害 | |
| JP2008523102A5 (zh) | ||
| JPWO2019177117A1 (ja) | 咳嗽の治療のための医薬 | |
| JP7222042B2 (ja) | ５′－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法 | |
| JP2006510606A5 (zh) | ||
| JP2006509743A5 (zh) | ||
| US20110038832A1 (en) | Method for treatment of macular degeneration using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione | |
| ES2215327T3 (es) | Composicion de medicamento inmunomodulador. | |
| TW200418455A (en) | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration | |
| WO2021214950A1 (ja) | 精神疾患を治療、予防又は管理するための医薬組成物 | |
| JP2007509932A5 (zh) | ||
| US20030212050A1 (en) | Prophylactic treatment of migraine | |
| JPS6296424A (ja) | 改良された抗炎症組成物 | |
| WO1998009628A1 (en) | Methods for inhibiting cardiac fibroblast growth and cardiac fibrosis | |
| JP2009143929A (ja) | 睡眠障害の予防・治療剤 | |
| JP2003503343A (ja) | 治療剤 | |
| JP2000355551A (ja) | 医薬組成物 | |
| JP2012506404A (ja) | 片頭痛処置用組み合わせ剤 | |
| KR20220166203A (ko) | 퇴행성 안질환의 예방 또는 치료용 약학적 조성물 | |
| JP2002514208A (ja) | 痴呆の治療及び予防におけるシクロオキシゲナーゼ−２阻害剤の使用方法 | |
| WO2001066110A2 (en) | METHOD FOR THE TREATMENT OF RENAL DYSFUNCTION WITH sPLA2 INHIBITORS | |
| JPH07508997A (ja) | 抗ウイルス剤の組み合わせ | |
| JPH1192381A (ja) | 心不全の予防・治療剤 |